α-Galactosidase A deficiency in Dutch patients on dialysis: A critical appraisal of screening for Fabry disease

Nephrology Dialysis Transplantation

Volumn 18, Issue 8, 2003, Pages 1581-1584

  Linthorst, Gabor E ^a   Hollak, Carla E M ^a   Korevaar, Johanna C ^a   van Manen, Jeanette G ^b   Aerts, Johannes M F G ^a   Boeschoten, Els W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

galactosidase A; Fabry disease; Lysosomal storage disorder; Prevalence; Screening

Indexed keywords

ALPHA GALACTOSIDASE;

ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; ENZYME THERAPY; FABRY DISEASE; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; SCREENING;

COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FABRY DISEASE; HUMANS; KIDNEY DISEASES; MALE; NETHERLANDS; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0041352960     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg194     Document Type: Article

References (14)

1. Desnick RJ, Ioannou YA, Eng ME. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th edn. Vol. 3. New York, McGraw-Hill 2001; 3733-3774
2. Tsakiris D, Simpson HK, Jones EH et al. Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996; 11 [Suppl 7]: 4-20
3. Thadhani R, Wolf M, West ML et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249-255
4. Utsumi K, Kase R, Takata T et al. Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 1999; 4: 49-51
5. Renine, the comprehensive Dutch dialysis registry. Statistical report 2002. 1-1-2002
6. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16
7. Schiffmann R, Kopp JB, Austin HA, III et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-2749
8. Termorshuizen F, Korevaar JC, Dekker F et al. Time trends in initiation and dose of dialysis in end-stage renal disease patients in the Netherlands. Nephrol Dial Transplant 2003; 18: 552-558
9. Spence MW, Goldbloom AL, Burgess JK et al. Heterozygote detection in angiokeratoma corporis diffusum (Anderson-Fabry disease). Studies on plasma, leucocytes, and hair follicles. J Med Genet 1977; 14: 91-99
10. Desnick RJ, Allen KY, Desnick SJ et al. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973; 81: 157-171
11. Walters BAJ, Prichard M, McCardle H, Richards SM, Bosch JP. Prevalence of reduced plasma α-galactosidase activity in a cohort of male patients on hemodialysis (HO) in the United States. Abstract, Annual Clinical Genetics Meeting, of the American College of Medical Genetics, March 2002
12. Spada M, Pagliardini S. Screening for Fabry disease in end-stage nephropathies. J Inher Metabol Dis 2002; 25 [Suppl I]: 113
13. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002; 359: 881-884
14. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775